Key Takeways U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...